Why are there still inconsistencies in the way different national GLP compliance monitoring programmes inspect multi-site studies?

Where inconsistencies continue to arise, these may be the result of a country’s specific regulatory requirements and should be discussed with the Compliance Monitoring Authority (CMA) concerned.